Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
— Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers — FOSTER CITY, Ca...